Next, we explored whether our tumor‐based prediction tool can predict CDK4 modification profiles and PD0332991 sensitivity when applied to the gene expression profiles acquired from RNA extracted from our panel of 20 cell lines (accession GSE87006). The gene discussed is CDK4; the disease is neoplasm.